A systematic overview of chemotherapy effects in colorectal cancer.
about
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancerIrinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for advanced and/or metastatic colorectal cancerIrinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for advanced and/or metastatic colorectal cancerAdjuvant Therapy for completely resected Stage II Colon CancerPeptide Vaccine Therapy in Colorectal Cancer2-deprenyl-rheediaxanthone B isolated from Metaxya rostrata induces active cell death in colorectal tumor cellsComparison of Nanostring nCounter® Data on FFPE Colon Cancer Samples and Affymetrix Microarray Data on Matched Frozen Tissues.Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement.A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver.Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement.A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastasesA 5-gene classifier from the carcinoma-associated fibroblast transcriptomic profile and clinical outcome in colorectal cancer.Clinical value of F-FDG PET/CT in assessing suspicious relapse after rectal cancer resectionSix-year experience of a nurse-led colorectal cancer follow-up clinic.A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study.The timing of introduction of pharmaceutical innovations in seven European countriesGrowth differentiation factor 15: a prognostic marker for recurrence in colorectal cancerCurrent treatment for liver metastases from colorectal cancer.Palliative treatment of patients with colorectal cancer.Follow-up after colorectal cancer surgery.Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer.Bax expression is a candidate prognostic and predictive marker of colorectal cancer.A network-based gene expression signature informs prognosis and treatment for colorectal cancer patients.Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report.Adjuvant chemotherapy in rectal cancers: why a standard in the US and not in Europe?ColoFinder: a prognostic 9-gene signature improves prognosis for 871 stage II and III colorectal cancer patients.Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study.Current role of antibody therapy in patients with metastatic colorectal cancer.Cost-effectiveness of adjuvant chemotherapy with uracil-tegafur for curatively resected stage III rectal cancer.Calnexin, an ER-induced protein, is a prognostic marker and potential therapeutic target in colorectal cancer.A study of lymph node ratio in stage IV colorectal cancerReduced ATR or Chk1 expression leads to chromosome instability and chemosensitization of mismatch repair-deficient colorectal cancer cells.A phase II study of irinotecan, 5-fluorouracil and leucovorin for treatment in patients with previously untreated advanced colorectal cancer.The Management and Prognostic Prediction of Adenocarcinoma of Appendix.miR-217 regulates tumor growth and apoptosis by targeting the MAPK signaling pathway in colorectal cancer.Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or chemotherapy with targeted therapy.Pregnane X receptor is associated with unfavorable survival and induces chemotherapeutic resistance by transcriptional activating multidrug resistance-related protein 3 in colorectal cancer.Metastatic colorectal cancer: current treatment and future options for improved survival. Medical approach--present status.Prospective Dutch colorectal cancer cohort: an infrastructure for long-term observational, prognostic, predictive and (randomized) intervention research.Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity.
P2860
Q24186145-CA677A4E-8DF3-4D33-9437-5834AC4AC2FAQ24200737-E2D8EFE3-0AFF-4020-B4AE-97F605EC3843Q24234555-DD2BFFC6-C781-4725-B85D-080871FB6770Q24242231-399F5BC8-DDA0-42D2-9907-5EF5E4EC848CQ26830336-B12145FE-5D55-401F-8264-834A449CAE9DQ28533805-2CF7571F-124A-4820-9E4E-F5E349E838F4Q31095892-F8182A57-61E2-4056-BCE6-EF92994B6813Q33388487-EE7E25BA-0B95-445E-904E-DC3C1A9E56DFQ33390290-8FB50023-C38E-4DA0-927B-797769EF8D0BQ33392260-4BF0CB59-98D9-482B-869A-CDA3F516E011Q33405667-494C7B1C-7A5D-447E-8ED8-986C6A591FA7Q34227755-DC776AB1-F9B4-43B4-9EE6-CE910A525952Q34390831-656783F7-4BF7-4227-9C52-19398AF15D4CQ34399187-90B13651-7218-4696-91FB-2934718BCD16Q34798367-6A287D3B-DF81-4B68-8187-CF36D6FD1A5BQ34805943-51065519-4F06-42DB-83C0-A3686FD6D49FQ35006757-0E8D615C-0DE8-41B1-A1F1-8F1A0F01BA90Q35047600-B5A13315-ECC7-43E6-9A9E-CCC1BF7B864DQ35111182-606A322D-3409-41A6-A681-F4A0C99C6451Q35669537-EAE83CC4-A687-4251-B840-D48CC6BD703FQ36073367-EE16E937-C7ED-4A6F-B6E4-8D043BB752ECQ36097096-85613773-3769-4F09-A255-676F3E7FE3E3Q36109706-44D09327-DFA1-477F-AC50-39296791F8D9Q36217126-626CA132-4D0C-4946-97AE-94B067A7F05EQ36303863-D182F0C5-B22E-4191-A0A5-630F3A45C511Q36691267-34789729-BB92-42BB-BC15-C9B71140D70CQ36694446-1C78DF88-D5BC-4DE9-AE6E-059F1231BAD5Q36832121-F841E3BD-FDA8-4744-9C0B-60C2EEDFD91CQ36944056-B8FA7C40-E06E-4870-AD0B-245267821BFCQ37059607-2988BA21-AC58-42D4-BA68-00B0DEB8CF23Q37078321-063C7BDF-2E90-41FB-A63D-CDA33A744695Q37327269-36AC2830-D361-4E30-A6E8-1432BED9A86AQ37341713-C14530EB-BD77-4B08-BF6D-0F66929CB243Q37508586-E8F27834-194D-457B-ADA7-37D176E5F7B6Q37582210-C9FDFA2E-A111-4DD5-9574-AADCE772D571Q37677564-6A0EAF71-197E-4CA9-B4DD-2EDA46848944Q37728678-02008190-4D34-496F-987D-3EE0A2C41ABFQ37975508-A7AC6BA1-36A1-4B3E-AB8D-270C59D03DD8Q38377842-DD1653FD-D91F-4EEC-9716-6B507803286CQ38930537-A664345A-1586-4475-8F7A-02EB624C8E6C
P2860
A systematic overview of chemotherapy effects in colorectal cancer.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
A systematic overview of chemotherapy effects in colorectal cancer.
@ast
A systematic overview of chemotherapy effects in colorectal cancer.
@en
A systematic overview of chemotherapy effects in colorectal cancer.
@nl
type
label
A systematic overview of chemotherapy effects in colorectal cancer.
@ast
A systematic overview of chemotherapy effects in colorectal cancer.
@en
A systematic overview of chemotherapy effects in colorectal cancer.
@nl
prefLabel
A systematic overview of chemotherapy effects in colorectal cancer.
@ast
A systematic overview of chemotherapy effects in colorectal cancer.
@en
A systematic overview of chemotherapy effects in colorectal cancer.
@nl
P2093
P1433
P1476
A systematic overview of chemotherapy effects in colorectal cancer.
@en
P2093
L Hafström
P Ragnhammar
SBU-group. Swedish Council of Technology Assessment in Health Care
P304
P356
10.1080/02841860151116367
P577
2001-01-01T00:00:00Z